The plant family Amaryllidaceae occupies a privileged status within the botanical hierarchy due to its horticultural and ornamental appeal, as well as its widespread usage in the traditional medicinal practices of indigenous peoples across the globe. Of greater significance are the unique, structurally-diverse alkaloid constituents produced by members of the family, which has spawned several biologically significant molecules. In this regard, the Alzheimer's drug galanthamine has gained much prominence due to its selective and reversible inhibitory interaction with the enzyme acetylcholinesterase (AChE), of significance in the progression of neurodegeneration associated with Alzheimer's disease (AD). The lycorine series of compounds within the family have recently emerged as novel inhibitors of AChE, in some instances with higher levels of activity compared with the commercial drug galanthamine, making them attractive targets for natural product and synthetically-driven structure-activity relationship studies. This brief survey traces the emergence of lycorine compounds over the past decade as promising leads in the therapeutic approach towards AD and their possible future advancement onto the clinical stage.
The impact of dementia related illnesses such as Alzheimer's disease (AD) on the global healthcare sector is staggering, affecting one in twenty people over the age of 65 and one in five over the age of 80 [1] . There are an estimated 35.6 million people worldwide with dementia and this is forecast to rise to over 115 million by 2050 [2] . Sixty percent of people with dementia presently live in developing countries [1] . According to Alzheimer's Disease International (ADI), the total estimated worldwide cost allied to dementia in 2010 was US$604 billion [2] . Given the gravity of the situation, the search for effective remedies has gained increasing impetus over the past decade [3] . According to the 'cholinergic hypothesis', Alzheimer's disease is associated with cholinergic insufficiency [4] . This serves as the rationale for use of cholinergic agonists and cholinesterase inhibitors for the symptomatic treatment of AD [3] . Despite significant advances in the experimental approaches towards AD, acetylcholinesterase (AChE) inhibitor regimens remain steadfast as the therapeutic choice in the treatment of this degenerative disease [5] .
The plant family Amaryllidaceae is richly endowed with an assortment of structurally diverse alkaloid structures all of which are related as a consequence of their biogenesis from the common amino acid-derived precursor norbelladine 1 (Figure 1 ) [6] . Galanthamine (2) , lycorine (3) and crinine (4) are characteristic of the three major groups of compounds within the family, distinct from the four minor group representatives homolycorine (5), tazettine (6) , montanine (7) and cherylline (8) [7] . Galanthamine has received considerable attention in both the public and scientific media since its approval by the FDA as a schedule drug in the treatment of AD [3] . This biologically privileged status was drawn out of its selective and reversible inhibition of AChE, of significance in the progression of neurodegeneration associated with AD [4] . Details of its mode of action as well as its interaction at the active site are now clearly defined due to the innovative work of Sussmann et al. [8] and Greenblatt et al. [4] . These investigators utilized X-ray crystallographic techniques to probe the complexation of galanthamine within Torpedo californica (Tc) AChE, thus elucidating essential elements of this inhibitory pharmacophore [4, 8] .
Since these findings, and because of their structural diversity, alkaloids of the Amaryllidaceae have emerged as attractive targets for probing AChE enzyme interactions [9] [10] [11] [12] [13] [14] . Such independent studies ratified the galanthamine series of compounds as the most potent, but also uncovered other members of the family with significant levels of inhibition. Lycorine (3) is the most common alkaloid across the Amaryllidaceae with a broad spectrum of 960 Natural Product Communications Vol. 7 (7) 2012
Nair & Van Staden biological properties, including antiviral [15] , antifungal [16] , antiparasitic [17] and anti-inflammatory [18] activities, as well as antifeedant [19] and cell growth inhibitory effects [20] . As a chemoprotective agent, it shows much potential as an antiproliferative agent in a number of cancer cell lines [21] [22] [23] ; notably manifesting this activity via the apoptotic mechanistic pathway [22, 24, 25] . During the past few years, both natural and semi-synthetically derived analogues of lycorine have been recorded as potent inhibitors of AChE [9] [10] [11] [12] [13] [14] , in some cases with superior IC 50 s compared with the galanthamine standard, as measured by the Ellman assay [26] . As such, this brief survey aims to piece together our contribution in this area [10] [11] [12] [13] [14] , together with those of others in highlighting this novel class of AChE inhibitors resident within the Amaryllidaceae group of alkaloids.
The potency of galanthamine (2) as an AChE inhibitor (IC 50 1.07 M) is striking, and seen to be more effective than most of the other Amaryllidaceae alkaloid representatives listed in Table 1 [9] . Interestingly, the 9-hydroxy analogue, sanguinine (9) , is ten times more active than galanthamine, but its low natural abundance has impeded its advancement onto the clinical stage [9] . Amongst the crinane compounds screened, the -5,10b-ethano variant epivitattine (11) had the lowest IC 50 value (239 M), more active than the pick of the -crinanes crinine (4) (IC 50 461) and crinamidine (10) (IC 50 300) [10] . Of the minor groups of compounds screened, only tazettine (6) (IC 50 705) and cherylline (8) (IC 50 407) had detectable levels of AChE inhibition [10] .
The first report on AChE inhibition in the lycorine series of compounds described the moderate activity of ungiminorine (17) (IC 50 86 M) [27] . Subsequent work by Lopez et al. [9] uncovered assoanine (22) (IC 50 3.87), and to a lesser extent oxoassoanine (23) (IC 50 47.21), as a strong inhibitor, whilst pseudolycorine (18) , with an IC 50 value of 152.32 M, was less effective at exerting this effect, and 2-acetoxypseudolycorine (19) was seen to have no observable effect on AChE (Table 1 ). In addition to this, hippadine (24) , the A-ring methylenedioxy variant corresponding to oxoassoanine (23), did not interact with AChE, as shown by Kissling et al. [28] . Interestingly, the trimethoxy-substituted pseudolycorine analogue galanthine (20) was only recently shown to possess moderate AChE activity (IC 50 63.1) [29] , while the related C-3/C-4 -epoxide incartine (21) was void of activity [30] . Furthermore, recent studies also outlined the inability of polyhydroxylated D-seco-lycorine analogues, such as narciclasine (26) (Figure 1 ), to interact with AChE [12, 13] , in contrast to the moderate activity (IC 50 78.9) very recently observed for the related unsaturated phenanthridone narciprimine (25) [14] . A major stride in this direction came originally in 2004 when we described the potent AChE inhibitory ability of 1-acetoxylycorine (14) (IC 50 0.96), with much lesser effects observed for lycorine (2) and 1,2diacetoxylycorine (15) with IC 50 values set at 213 and 211 M, respectively [10] . Interestingly, a dramatic modulation in activity (>100 fold) was observed on reverting to the 2-acyl functionality as in 2-acetoxylycorine (16) (IC 50 169) [11] .
In the synthetic realm, partially-sequestered ring-D analogues such as 31, derived from 1,2-diacetoxylycorine, as outlined in Scheme 1, was shown for its striking AChE inhibitory ability with an IC 50 of 2.66 M (Table 1 ) [31] . In this synthetic sequence, quaternization of the basic nitrogen atom in 1,2-diacetoxylycorine (15) displacement of the chloride group with sodium acetate in DMSO and reductive cleavage of the carbamate with a zinc/acetic acid mixture afforded triacetate 29 in 58% yield. Reductive Nmethylation followed by base hydrolysis then gave the target secotriol 31 in 90% isolated yield [31] .
Also in the synthetic direction, a novel silylation strategy recently developed by us allowed chemo-regioselective placement of a tertbutyldimethylsilyl (TBS) group at C-2 in lycorine (Scheme 2), providing access to C-1 and C-2 differentially functionalized analogues for structure-activity relationship (SAR) study purposes [12, 13] . This operation utilized the greater reactivity of the allylic pseudoequatorial 2-hydroxy group over the axially-orientated homoallylic C-1 hydroxyl, in addition to the bulkiness of the incoming TBS electrophile leading to 2-(O)-TBS-lycorine (12) in 56% isolated yield. Acetylation at C-1 afforded 1-acetoxy-2-(O)-TBS-lycorine (13) , which was subsequently desilylated with tetrabutylammonium fluoride (TBAF) leading to 1-acetoxylycorine (14) in near quantitative yield, in the event also providing a facile synthesis of the rare natural compound 14. Acetylation of 14 then afforded 1,2-diacetoxylycorine (15) in 97% isolated yield. Similarly, C-1 benzoyl analogues 32-34 ( Figure 1 ) were accessed in high yields via the same chemoselective silylative strategy outlined in Scheme 2 [12, 13] .
These silylated analogues were uncovered as novel inhibitors of AChE, all with Ki values less than 1 M (Table 1) , and 1-acetoxy-2-(O)-TBS-lycorine (13) (Ki 0.34 M) was established as the most potent inhibitor to date within the lycorine series of compounds [12, 13] . These fascinating findings collectively highlight several core features attending the AChE inhibitory pharmacophore resident within the lycorine series of alkaloids. Moreover, the potency of functionalized lycorine analogues has been based largely on structural similarities to galanthamine and regions of overlap along their respective pharmacophores, as shown by molecular modeling and docking studies [11] .
X-ray crystallography of AChE isolated from Torpedo californica, showed that the active site accommodates a catalytic triad (Ser200, His440, Glu327) located at the bottom of a deep and narrow gorge lined with aromatic residues and a subsite including Trp84 located near the bottom of the cavity [8] . Trp84 has been identified as the binding site for acetylcholine [8] . The structure of the galanthamine-TcAChE complex showed that galanthamine binds at the base of the active site gorge, interacting with both the acylbinding pocket and the indole ring of Trp84 [4] . While the tertiary amine group did not interact with Trp84, a - interaction was observed for the double bond of the cyclohexene ring with Trp84, and the methoxy group of galanthamine was seen to occupy the acetyl-binding pocket in acetylcholine [4] .
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Natural Product Communications Vol. 7 (7) [9, 29] . Superposition of minimum energy conformations showed partial overlap for the methoxyl of galanthamine and the methylenedioxy of 1-acetoxylycorine (14) [11] , thus supporting the observations made above for differential A-ring substitution patterns. In terms of ring-B functionalization, a direct comparison could be made for the variants assoanine (22) (IC 50 3.87 M) and oxoassoanine (23) (IC 50 47.21) where introduction of the C-6 oxogroup had a deleterious effect on AChE inhibition [9] . As noted above, the C-4/C-4a double bond in galanthamine was seen to have - interactions with Trp84 [4] , and since the lycorine double bond is in a proximally similar position it may be able to elicit a similar response at the active site. Positioning of the double bond was seen to have a profound effect on AChE inhibition, as shown for ungiminorine (17) (IC 50 86 M) [27] , lycorine (3) (IC 50 213) [10] and narciclasine (26) (not active) [12] , respectively. Although unsaturation in ring-C produced active compounds in assoanine (22) (IC 50 3.87 M), oxoassoanine (23) (IC 50 47.21) and narciprimine (25) (IC 50 78.9) [9, 14] , which was explained in terms of planarity generated through aromatization, partially saturated variants such as 1-acetoxylycorine (14) (IC 50 0.96) were far superior at AChE inhibition [10] . The importance of ring-D is apparent by direct comparison of the structures of assoanine (22) (IC 50 3.87 M) and narciprimine (25) (IC 50 78.9) [9, 14] , by which it was seen that introduction of the N,C-4 ethyl ether effects a ~20 fold increase in AChE activity. Furthermore, the semi-synthetic, partiallysequestered ring-D analogue 31 [31] , possessing a free C-4 hydroxyethyl chain, was similar in activity (IC 50 2.66 M) to assoanine (22) [9] , highlighting the requirement of the ethyl fragment within the lycorine series of inhibitors.
The dramatic spike in activity in going from lycorine to analogue 12 (Ki=0.86 µM) suggests that the C-2 area of the molecule must occupy a bulky, lipophilic pocket within the active site to accommodate the TBS group [12] . This substitution contrasts sharply with 2-acetoxylycorine (16) , with an IC 50 value of 169 µM [11] , suggesting that small, polar groups at C-2 may impede inhibition. Acylation at C-1 had a pronounced effect on inhibition (Table 1) , affording in compounds 13 (Ki=0.34 µM) and 32 (Ki=0.39) the most potent inhibitors of AChE identified to date within the lycorine series [12] . Superposition of minimum-energy conformations of galanthamine (2) and 1-acetoxylycorine (14) indicated that the acetate and nitrogen atom of the latter superimpose on the hydroxyl group and the nitrogen atom of galanthamine, respectively [11] . Therefore, it is possible that the 1acetyl group may be involved in hydrogen bonding in a manner similar to that elegantly demonstrated for the hydroxyl of galanthamine complexed within TcAChE [4] . Benzoate 32 may similarly also be involved in hydrogen bonding via the carbonyl, in addition to participating in - interactions. The drop in activity (~1.3 fold) observed upon desilylation to compounds 14 and 33 respectively, endorses the silylative lipophilic effect observed for 12, 13 and 32 [12] . Acylation at C-2 had a pronounced effect on inhibition since diacetate 15 was substantially less active (IC 50 211 µM), and 34 (Ki=0.97) was almost half as potent as hydroxy benzoate 33 (Table 1 ) [12] . These results further vindicate the requirement for a lipophilic binding interaction in the C-2 area of the molecule [12] .
In summary, a more comprehensive view has emerged of the potent AChE inhibitory pharmacophore resident within the lycorine series of Amaryllidaceae alkaloids. These enhanced activities are in part due to the structural similarities of the lycorine and galanthamine series of compounds, as well as the possibility of overlap along significant areas of their respective pharmacophores. SAR studies utilizing both natural and semi-synthetically derived analogues allowed for a refinement of the ingredient pharmacophoric elements, the most striking of which is a lipophilic silylative effect seen in the C-2 region of the molecule which, in conjunction with acylation (acetylation or benzoylation) at C-1 afforded the most potent AChE inhibitors recorded to date within the lycorine series, with Ki values as low as 0.34 µM. These collective findings should prove significant in advancing a lycorine AChE inhibitor candidate onto the clinical market. 
